The Gelesis team includes proven entrepreneurs and leaders in obesity & metabolism, healthcare and commercialization

LEADERSHIP TEAM

Yishai Zohar - Chief Executive Office & Founder

A seasoned entrepreneur, Mr. Zohar has over 25 years’ experience in the development of industry innovating companies. Mr. Zohar is the Founder, Chief Executive Officer and a Board of Directors member of Gelesis Inc., a Boston-based biotechnology company developing a proprietary hydrogel platform designed to leverage mechanobiology along the GI tract to potentially alter the course of chronic diseases including obesity, NAFLD/NASH and inflammatory bowel disease
Zohar led the company from formation and initial discovery as a co-inventor and shepherded the company and product through clinical studies and a landmark FDA clearance of lead product PLENITY™ as an aid for weight management. PLENITY is the first and only FDA-regulated treatment cleared for use by all adults with excess weight (BMI between 25-40 kg/m2) with or without the presence of comorbidities. Prior to founding Gelesis, Mr. Zohar was a Co-Founder of PureTech Health (PRTC.L), a biopharma company developing groundbreaking therapeutics that target the Brain-Immune-Gut axis. In his role at PureTech he led the obesity/GI initiative which engaged leading experts to look at a broad landscape of technologies and approaches. This initiative led to the formation of Gelesis. Zohar has a degree in Business Administration from the College of Management Academic Studies (COMAS) in Tel Aviv and was an air force pilot ranked Captain in the Israeli Defense Forces.

David Pass, Pharm.D. – Chief Operating Officer and Head of Commercial

Dr. Pass joins Gelesis with more than 20 years of commercial expertise across multiple therapeutic areas with a focus on diabetes and metabolics.
Dr. Pass gained a broad range of commercial experience from his time with Johnson & Johnson, and Bristol-Myers Squibb Most recently, Dr. Pass served as Vice President of Marketing at Boehringer Ingelheim (BI) for Diabetes, where he built a billion-dollar franchise. In this role, Dr. Pass also led the BI alliance with Eli Lilly & Company to develop and commercialize a portfolio of diabetes compounds in mid- and late-stage development. David received both his B.S. Pharmacy and Doctor of Pharmacy degrees from Philadelphia College of Pharmacy and Science. He resides in Ridgefield, Connecticut. He enjoys many interests outside work including cycling, snowboarding, golf and woodworking.

Harry L. Leider, M.D., M.B.A, FACPE - Chief Medical Officer

Harry L. Leider, M.D., M.B.A. joined Gelesis from Walgreens, where he was Chief Medical Officer and Group Vice President and provided executive leadership for the Company’s unique platform to impact the six million customers who visit a Walgreens store each day, as well as the two million customers who interact with Walgreens digitally.
Prior to joining Walgreens, Dr. Leider served as Chief Medical Officer and Senior Vice President of Ameritox, a national specialty laboratory providing medication monitoring services to physicians treating chronic pain and serious mental illness. Previously, he was Chief Medical Officer of XLHealth, a national Medicare Advantage plan that served seniors with common chronic illnesses. Dr. Leider speaks frequently to national audiences and is a core faculty member for the American Association of Physician Leadership where he also served as a recent past-President and Board Chairman. Dr. Leider has also served on the faculty of Harvard Medical School and the Johns Hopkins Carey School of Business. With over 25 years of experience as a senior healthcare executive for a variety of innovative healthcare companies, his passion is leveraging his business, leadership, and clinical skills to create programs, services, and intellectual property that improve the health of large populations at scale.

Elaine Chiquette, Pharm.D. – Chief Scientific Officer

Dr. Chiquette joins Gelesis with over 15 years’ experience in Medical Affairs within the pharmaceutical, biotechnology, and medical device industries.

Dr. Chiquette was involved in developing medical strategies for first-in-class launches like orlistat, GLP-1 agonist, amylin analog, endobarrier device, and metreleptin at Hoffman La Roche, Amylin Pharmaceuticals, Aegerion and GI Dynamics. In her leadership roles throughout the years, Dr. Chiquette built strong expertise in regulatory affairs for pharmaceuticals, biologics, and devices in both United States and Europe. Prior to launching her career in industry, Dr. Chiquette completed her pharmacy degree at Laval University in Quebec, a Pharm.D. At University of Texas Health Science Center at San Antonio, followed by a post-doctorate fellowship in Epidemiology. Dr. Chiquette served as Deputy Director for the San Antonio Evidence-Based Practice Center program for the US government Agency for Healthcare Research and Quality and authored several meta-analyses. In that capacity, Dr. Chiquette led the supportive evidence report for the National Institute of Health Obesity Guidelines in 1998 and co-authored the associated publications. Since then, her career, publications and interest has been focused on therapeutic options for cardiometabolic diseases.

Hassan Heshmati, M.D. - Executive Vice President, Endocrinology and Metabolism

Dr. Hassan M. Heshmati, has over 37 years of experience in clinical research in pharmaceutical companies (Essentialis, Carlsbad, CA and Sanofi-Aventis, Malvern, PA) and in academia (Mayo Foundation, Rochester, MN and university-affiliated hospitals, Paris, France).
His research activity has been related to pituitary tumor, gonadal function, dyslipidemia, hyperthyroidism, thyroid cancer, osteoporosis, obesity, and diabetes. Dr. Heshmati received his M.D. Degree from the University of Paris VI, Paris, France. He is Board Certified in Endocrinology.

Eyal Ron, Ph.D. - Head of Regulatory

Dr. Eyal S. Ron has over 20 years of experience in the development of devices, biomaterials, drugs and drug delivery systems.
He has in-depth understanding of total development process including project management, clinical trials, regulatory, formulation, drug delivery, QC and manufacturing scale-up. He has contributed to the formation of Argolyn Biosciences, Cerebrotec, Combinent Biomedical Systems, eNOS Pharmaceuticals, Focal, GelMed/Gel Sciences, InfiMed and Palmetto Pharmaceuticals. Dr. Ron holds a PhD in chemistry from Brandeis and completed a post-doctoral fellowship at MIT in the lab of Dr. Robert Langer. Currently he is an Adjunct Faculty at the Harvard-MIT Division of Health and Sciences and Technology.

Alessandro Sannino, Ph.D. - Co-inventor & Lead Project Scientist

Dr. Alessandro Sannino is a co-inventor of the GS100 technology, is Professor of Polymer Science and Technology and the director of the Bioslabs at the University of Salento.
Dr. Sannino is responsible for the Life Science division of the Puglia District of Technology and adjunct faculty at the Massachusetts Institute of Technology (MIT). He is also an advisor to the National Institute of Health, of the Italian Ministry of Health (Italian equivalent to the FDA). Dr. Sannino’s research activity is focused on macromolecular hydrogels, polymer microstructure modifications, tissue engineering constructs and cell-material interactions, has published over 100 scientific papers on these topics. He received his PhD at University of Naples and University of Washington on polymer technology, and did a post-doctoral fellowship at MIT.

See our scientific advisors